---
title: "12 Health Care Stocks Moving In Friday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294511751.md"
description: "In Friday's pre-market session, healthcare stocks showed significant volatility. Gainers included Replimune Group (REPL) up 134.6%, Moleculin Biotech (MBRX) up 17.64%, and Cuprina Holdings (CUPR) up 13.72%. Conversely, major losers featured Karyopharm Therapeutics (KPTI) plummeting 69.6%, Bioage Labs (BIOA) dropping 53.0%, and Nuwellis (NUWE) falling 39.33%. These movements reflect early trading activity ahead of the market open."
datetime: "2026-07-31T12:05:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294511751.md)
  - [en](https://longbridge.com/en/news/294511751.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294511751.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Friday's Pre-Market Session

### Gainers

-   **Replimune Group** (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session.
-   **Moleculin Biotech** (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of their outstanding shares is at $5.4 million.
-   **Cuprina Holdings (Cayman)** (NASDAQ:CUPR) stock increased by 13.72% to $3.02. The company's market cap stands at $7.1 million.
-   **Polaryx Therapeutics** (NASDAQ:PLYX) stock moved upwards by 11.62% to $2.4. The company's market cap stands at $107.1 million.
-   **VivoSim Labs** (NASDAQ:VIVS) stock moved upwards by 11.32% to $0.43. The company's market cap stands at $1.3 million.
-   **BioRestorative Therapies** (NASDAQ:BRTX) shares rose 10.42% to $0.25. The company's market cap stands at $5.7 million.

### Losers

-   **Karyopharm Therapeutics** (NASDAQ:KPTI) stock declined by 69.6% to $2.13 during Friday's pre-market session. The market value of their outstanding shares is at $158.8 million.
-   **Bioage Labs** (NASDAQ:BIOA) shares declined by 53.0% to $11.68. The market value of their outstanding shares is at $1.1 billion.
-   **Nuwellis** (NASDAQ:NUWE) shares fell 39.33% to $2.7.
-   **Myriad Genetics** (NASDAQ:MYGN) stock fell 37.81% to $3.34. The company's market cap stands at $507.1 million. As per the news, the Q2 earnings report came out yesterday.
-   **Monte Rosa Therapeutics** (NASDAQ:GLUE) stock declined by 27.03% to $16.55. The market value of their outstanding shares is at $1.9 billion.
-   **AirSculpt Technologies** (NASDAQ:AIRS) shares fell 17.53% to $4.0. The market value of their outstanding shares is at $342.1 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [NUWE.US](https://longbridge.com/en/quote/NUWE.US.md)
- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [CUPR.US](https://longbridge.com/en/quote/CUPR.US.md)
- [BIOA.US](https://longbridge.com/en/quote/BIOA.US.md)
- [PLYX.US](https://longbridge.com/en/quote/PLYX.US.md)
- [VIVS.US](https://longbridge.com/en/quote/VIVS.US.md)
- [BRTX.US](https://longbridge.com/en/quote/BRTX.US.md)
- [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md)
- [GLUE.US](https://longbridge.com/en/quote/GLUE.US.md)
- [AIRS.US](https://longbridge.com/en/quote/AIRS.US.md)

## Related News & Research

- [Moleculin highlights interim data from pivotal MIRACLE Phase 2/3 Annamycin trial in relapsed/refractory AML](https://longbridge.com/en/news/297191000.md)
- [Moleculin Biotech announces annual shareholder meeting](https://longbridge.com/en/news/296828733.md)
- [17:00 ETReplimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit](https://longbridge.com/en/news/296955124.md)
- [Walter V. Klemp Discloses Investment at Moleculin Biotech with 9.87% Stake](https://longbridge.com/en/news/296952835.md)
- [Nuwellis enters co-promotion, distribution pact with Atrility for AtriAmp device](https://longbridge.com/en/news/296914542.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**